Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Home Page: www.bms.com
430 East 29th Street
New York,
NY
10016
United States
Phone:
212 546 4000
Officers
| Name | Title |
|---|---|
| Dr. Giovanni Caforio M.D. | Chairman & CEO |
| Mr. David V. Elkins | Exec. VP & CFO |
| Ms. Sandra Leung Esq. | Exec. VP & Gen. Counsel |
| Dr. Christopher S. Boerner | Exec. VP & Chief Commercialization Officer |
| Mr. Rupert Vessey BCH, BM, DPHIL, M.A. | Exec. VP and Pres of Research & Early Devel. |
| Mr. Greg Meyers | Exec. VP and Chief Digital & Technology Officer |
| Mr. Timothy Power | VP & Head of Investor Relations |
| Ms. Cari Gallman | Sr. VP & Chief Compliance and Ethics Officer |
| Ms. Ann M. Powell Judge | Exec. VP & Chief HR Officer |
| Mr. Jitendra Tyagi | Head of US Drug Makers - India |
Exchange: XETRA
Country: DE
Currency: Euro (€)
| Forward PE: | 10.0604 |
|---|---|
| Trailing PE: | 23.3965 |
| Price-to-Book MRQ: | 5.1795 |
| Price-to-Sales TTM: | 3.2494 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 32200 |